To determine if exogenous gamma interferon is effective in immunosuppressed mice infected with Trypanosoma cruzi, recombinant murine gamma interferon was administered to cyclosporin-treated mice with either acute or chronic T. cruzi infection. Gamma interferon significantly decreased parasitemia and prevented death in acutely infected mice. Parasitemias and mortality of mice treated with both gamma interferon and cyclosporin were similar to those of immunocompetent controls. In chronically infected mice, cyclosporin treatment produced significantly more organ explant cultures positive for T. cruzi. Fewer positive cultures, particularly for spleen and heart, were obtained from cyclosporin-treated mice when they also received gamma interferon. Ketoconazole treatment of mice resulted in no positive cultures. Cyclosporin treatment did not prevent activation of peritoneal macrophages by parenteral gamma interferon, nor did it have a consistent effect on serum titers of alpha/beta or gamma interferon in response to a second challenge inoculum of T. cruzi. These data indicate that exogenous gamma interferon suppresses acute and chronic T. cruzi infection in cydosporin-treated mice but that gamma interferon is not as effective as the relatively specific antimicrobial ketoconazole. Gamma interferon activates macrophages despite cyclosporin treatment, and its effects appear to be tissue specific.
Cyclosporin inhibits many T-cell-dependent functions including delayed hypersensitivity (33, 36) , allograft rejection (4) , and production of cytokines such as interleukins-1, -2, and -3 and gamma interferon (IFN--y) (5, 6, 33) . Cyclosporin is used widely for prevention of graft rejection in transplant recipients, with improved patient and transplant organ survival, but opportunistic infections still complicate therapy. Disease due to opportunistic infection may result from recent acquisition of a new pathogen or from reactivation of infection acquired before transplantation. Partial reconstitution of the immune system with cytokines such as IFN-y has become feasible because of recombinant technology and potentially may prevent development of disease due to infection. IFN--y is currently being used in therapeutic trials for patients with cancer or infected with human immunodeficiency virus or parasites (1, 8, 22, 25, 26) . We investigated the effects of administration of recombinant murine IFN--y (rmuIFN-,y) to cyclosporin-treated mice with either acute or chronic infection with Trypanosoma cruzi, an intracellular pathogen known to be inhibited by rmuIFN--y in vitro and in vivo in immunocompetent mice (20, 30) . The goals of the study were to determine if administration of IFN--y could suppress parasitemia and prevent death in acutely infected, immunosuppressed mice and if IFN--y could suppress chronic infection in immunosuppressed mice and/or regulate the distribution of T. cruzi to organs.
MATERIALS AND METHODS
Mice and T. cruzi. Swiss Webster and C3H/HEN mice were obtained from Charles River (Wilmington, Mass.) or Simonsen Laboratories (Fremont, Calif.) and were 6 to 8 weeks of age when used. C3H/HEN mice were used in experiments with the chronic infection since parasitemia that can be quantitated by light microscopy can be induced with * Corresponding author. relatively short courses of cyclosporin A treatment in this strain but not in Swiss Webster or C57BL/6 mice (20a).
The highly virulent Y strain (21) used in all experiments is maintained by weekly syringe passage in Swiss Webster mice and produces peak parasitemia on day 7 of infection, at which time blood is collected in Hanks balanced salt solution (HBSS; GIBCO Laboratories, Grand Island, N.Y.) with 3.4% sodium citrate (Sigma Chemical Co., St. Louis, Mo.). The trypomastigotes in blood are counted in a hemacytometer, diluted with HBSS-citrate to the desired concentration, and then used to infect mice by intraperitoneal (i.p.) injection.
To produce chronically infected mice, 20,000 trypomastigotes from blood were injected i.p. into mice. Twenty-four hours later, primaquine (Sigma) was added to the drinking water (0.25 mg per day per mouse) for 6 days to prevent death due to the acute infection. Mice were considered to have passed into the chronic stage of infection when parasitemia was subpatent without mortality due to the infection, usually by 6 to 8 weeks of infection with the Y strain.
Macrophages were challenged with T. cruzi obtained from L-cell tissue cultures (13 (Fig. 1) . The dose of cyclosporin (150 mg/kg of body weight per day subcutaneously) was shown previously to increase parasitemia markedly in this model of acute T. cruzi infection (10, 17) . The high inoculum of T. cruzi was chosen to ensure that parasitemia could be measured by light microscopy. The dose of rmuIFN--y (5,000 U i.p. every other day) was shown previously to decrease mortality and/or parasitemia for mice infected with Toxoplasma gondii or T. cruzi (2, 14, 20) . Doses of 102 U or fewer were found ineffective in T. cruzi infection (20) , and no significant differences were found between 103 and 104 U in prolongation of time to death (20) .
Controls and cyclosporin-treated mice died at about the same rates, as expected from previous experiments with this model (17) . rmuIFN--y-treated mice had a significant (P < 0.05) but short prolongation of time to death. Treatment of cyclosporin-treated mice with rmuIFN--y ameliorated infection in that time to death resembled that of mice treated with rmuIFN--y only and was significantly less than that for mice treated with cyclosporin only. Parasitemia results confirmed that cyclosporin treatment and rmuIFN--y treatment significantly increased and decreased parasitemia, respectively (Table 1) (19) and to suppress the chronic infection (12) . Four groups of C3H/HEN mice infected for 3 months were treated with cyclosporin (150 mg/kg/day), rmuIFN--y (50,000 U i.p. twice a week) and cyclosporin, ketoconazole (60 mg/kg/day by gavage) and cyclosporin, or olive oil for 4 weeks. Treatment was followed by sacrifice and explant culturing during the next 2 weeks. The average time from end of treatment to explant culture was the same for all groups. During treatment, all the mice treated with cyclosporin developed only patent parasitemia, none of the mice treated with ketoconazole and cyclosporin developed patent parasitemia, and some mice treated with either olive oil or the combination of rmuIFN--y and cyclosporin developed patent parasitemia.
Skeletal muscle, omental fat, bladder-ureter, spleen, diaphragm, and heart were sampled for explant culture (Table  2 ). In controls, cultures of skeletal muscle and spleen were frequently positive, whereas few other organs were positive. Cyclosporin treatment produced positive cultures in a large proportion of organs (P < 0.01 compared with controls). rmuIFN--y treatment of cyclosporin-treated mice produced fewer positive cultures of spleen and heart (P < 0.05 for spleen and heart cultures combined) but had no apparent effect on other organs. The effect of ketoconazole was substantial, as none of the explanted organs were positive despite concurrent treatment with cyclosporin (P < 0.01 compared with controls). Thus, cyclosporin was a potent immunosuppressive agent in chronic infection, as assessed by explant cultures. rmuIFN--y appears to have a limited effect, especially when compared with the antimicrobial agent ketoconazole. The anti-T. cruzi effect of rmuIFN-y on spleen compared
with other organs was also demonstrated in nonimmunosuppressed, chronically infected Swiss Webster mice (Table 3) .
When the results given in Tables 2 and 3 are combined, spleen cultures from rmuIFN-y treated mice are seen to be significantly less frequently positive than spleens from cyclosporin-treated and control mice (P < 0.01).
Effect of cyclosporin on serum titers of IFN-'y. Since levels of IFN activity in serum of acutely infected mice are low and difficult to measure (11, 20a, 34) , a protocol similar to that used by Nakane et al. (24) to induce higher levels of IFN--y in serum of mice acutely infected with Listeria monocytogenes was used. Swiss Webster mice were infected i.p. with 103 trypomastigotes from blood and were treated with either cyclosporin (150 mg/kg subcutaneously or by gavage) or olive oil on days -1, 0, and + 1. Six days later, the mice were injected intravenously with 106 tissue culture T. cruzi, and 6 hours later, serum was collected. Control mice produced both IFN-a/p and IFN--y in response to the second injection of T. cruzi. In a total of 10 experiments, cyclosporin treatment had no consistent effect on the serum titer of total IFN activity or the titers of IFN-a/I or IFN-y. Typical titers of IFN activity were 6 to 64 U/50 ,ul of serum sample. Treatment with anti-IFN-alp typically decreased the titer fourfold, whereas treatment with anti-IFN--y either did not change the titer or decreased it two-to fourfold. Acidifying the sample to pH 2 decreased the titer twofold. In addition, injection of 50,000 U of rmuIFN--y i.p. on day 2 of infection did not affect IFN response in the serum, regardless of cyclosporin treatment. Effect of cyclosporin on activation of macrophages by parenteral rmuIFN-y. We reported previously that cyclosporin treatment of mice acutely infected with T. cruzi did not prevent activation of peritoneal macrophages caused by the infection (18) . To evaluate the effect of cyclosporin treatment on the activation of peritoneal macrophages by parenteral rmuIFN--y, mice were treated with cyclosporin (150 mg/kg/day subcutaneously) for 3 days and were injected i.p. 24 h later and challenged with phorbol myristate acetate. The mean change in absorbance (± standard error of the mean) was 0.036 ± 0.007 for rmuIFN--y-treated mice, 0.043 ± 0.009 for rmuIFN--y-and cyclosporin-treated mice, and 0.013 ± 0.012 for resident macrophages.
DISCUSSION rmuIFN--y treatment of immunocompetent mice with acute T. cruzi infection has been shown previously to significantly decrease parasitemias (20) and prevent death (30) . Results in this report extend these findings for acute infection in that rmuIFN--y suppressed parasitemias of cyclosporin-immunosuppressed mice to levels of parasitemia observed in immunocompetent mice. Furthermore, rmuIFN-,y prevented death due to T. cruzi in immunosuppressed mice when the inoculum of T. cruzi was sufficiently small. High inocula of T. cruzi were chosen to ensure measurement of parasitemia by light microscopy. Small inocula probably are more analogous to the subcutaneous inocula that cause clinical infection and likely result in gradual systemic release of organisms, a situation that contrasts with the effect of the i.p. injections used in this study.
The salutary results of treatment may have been limited by the doses of rmuIFN--y used. Lower mortality and parasitemia might have occurred if higher dosages of rmuIFN--y had been used, possibly because of greater anti-T. cruzi activity in nonphagocytic cells. Alternatively, higher dosages may not be more effective than a threshold dose. In particular, higher dosages of rmuIFN--y are not likely to be more effective by further enhancing the direct anti-T. cruzi activity of macrophages. The prime target of IFN--y appears to be the macrophage (14, 20, 31) , and the doses of rmuIFN--y used in our experiments were sufficient to activate macrophages to kill T. cruzi and toxoplasma 24 h after a single injection in vivo (10, 14; see Results above). Since only two doses of rmuIFN-,y prevented death from murine T. cruzi (Fig. 2) and toxoplasma infection (14) , the major effect of IFN--y is likely activation of macrophages early, before endogenous IFN-y and/or other cytokines generated in response to the infection activate macrophages. Higher dosages of rmuIFN--y or more injections later in the acute infection may not improve macrophage function with respect to controlling T. cruzi infection.
Interestingly, Reed (30) found that rmuIFN--y treatment of non-cyclosporin-treated mice acutely infected with T. cruzi restored plaque-forming-cell responses. Thus, treatment early in infection may restore some cell-mediated and humoral immune responses. Reed's studies did not determine whether the effect of rmuIFN--y was directly immunoregulatory or a result of the anti-T. cruzi activity of rmuIFN--y.
The route or method of administration of rmuIFN--y may be important. Murray recently reported that constant subcutaneous infusion of rmuIFN--y with an osmotic pump was superior to i.p. injection of rmuIFN--y in reducing liver parasite burden in a murine model of acute visceral leishmaniasis (23) .
Assessment of the effects of rmuIFN--y administration in chronic T. cruzi infection is more difficult than such assessment in acute infection. Chronically infected mice were treated with cyclosporin to induce parasitemia before rmuIFN--y treatment so as to use parasitemia and mortality as measures of treatment effectiveness, but this harsh model did not show a beneficial effect of rmuIFN--y. Alternatively, rmuIFN--y treatment was started earlier in cyclosporintreated mice, and explant cultures were used to assess outcome. rmuIFN--y treatment significantly reduced the number of spleen and heart cultures that were positive for T. cruzi but had little effect on other organs. These results suggest that the anti-T. cruzi effects of IFN--y may be organ, tissue, or cell specific. Peritoneal macrophages are activated by endogenous mechanisms to kill T. cruzi in chronic T. cruzi infection (9, 20a) . Thus, the benefit of rmuIFN--y treatment in chronic infection may need to be mediated through effects on cells other than macrophages.
Ketoconazole is a very potent anti-T. cruzi agent in vitro and in vivo. Ketoconazole can cure the majority of acutely infected mice (19) , but it appears to only suppress chronic infection (12) . As judged by explant cultures, ketoconazole was much more potent than rmuIFN--y. For serious T. cruzi infection, ketoconazole or standard anti-T. cruzi agents likely are preferable therapeutic agents, although possibly in combination with rmuIFN--y as it has been used in the treatment of humans with visceral leishmaniasis (1, 27) . However, in transplant and other immunosuppressed patients, prevention of disease due to infection may be a reasonable goal. For that purpose, when diverse intracellular pathogens threaten the patient, rmuIFN-y or other immunomodulatory agents may be effective and preferable to a number of different pathogen-specific agents, with their potentials for adverse effects.
